Genmab A-S

Genmab A-S

Yahoo Finance • 8 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption righ... Full story

Yahoo Finance • 10 days ago

Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab (CPSE:GMAB) released new subgroup data from its pivotal Phase 3 EPCORE FL-1 trial of epco... Full story

Yahoo Finance • 11 days ago

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymp... Full story

Yahoo Finance • 13 days ago

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups... Full story

Yahoo Finance • 19 days ago

Truist Assigns Buy Rating to Genmab (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target fro... Full story

Yahoo Finance • 26 days ago

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the tr... Full story

Yahoo Finance • last month

Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares. On May 7... Full story

Yahoo Finance • 2 months ago

Major Shareholder Announcement

Genmab A/S Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment M... Full story

Yahoo Finance • 2 months ago

DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push

Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company... Full story

Yahoo Finance • 2 months ago

Genmab Announces Financial Results for the First Quarter of 2026

Genmab A/S May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the... Full story

Yahoo Finance • 2 months ago

Genmab (GMAB) Rated Outperform on Oncology Pipeline

Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical t... Full story

Yahoo Finance • 2 months ago

Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Genmab A/S  is among the best biotech stocks. TheFly reported on April 22 that The Goldman Sachs Group raised its rating on GMAB from Neutral to Buy and... Full story

Yahoo Finance • 2 months ago

Anthropic Adds Novartis CEO to Board

The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year. Continue Reading... Full story

Yahoo Finance • 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; Apri... Full story

Yahoo Finance • 2 months ago

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab A/S Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovaria... Full story

Yahoo Finance • 3 months ago

Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citi upgraded Bilibili (BILI) to Buy f... Full story

Yahoo Finance • 3 months ago

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story

Yahoo Finance • 3 months ago

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly... Full story

Yahoo Finance • 3 months ago

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forw... Full story

Yahoo Finance • 4 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the t... Full story